Circassia is a world-class specialty biopharmaceutical business focused on allergy and respiratory disease. The Company has an established commercial infrastructure, marketed products, a pipeline of near-term therapies and a portfolio of next generation treatments targeting multi-$billion market opportunities. Circassia sells its novel, market-leading products for asthma management directly to allergy / asthma specialists in the United States and Germany. Its products are also promoted in a number of other countries by the Company’s international network of partners.
Circassia’s broad-based development pipeline includes a range of treatments for allergy and respiratory disease. Circassia’s most advanced next-generation immunotherapy is currently in phase III testing for cat allergy, and is the first in a new class of treatments, Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs). Three other SPIREs, targeting house dust mite, ragweed and grass allergies, have completed clinical proof-of-concept phase IIb studies. Circassia’s lead asthma product targets substitution of GSK’s FLIXOTIDE® pMDI, and UK approval is expected in December 2015. Circassia anticipates two further product filings in 2016, targeting direct substitution of SERETIDE® pMDI and SEREVENT® pMDI. The Company is also developing a number of novel treatments, including a fixed dose ‘triple’ combination containing an inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist.

Show more
Oxford, GB
Size (employees)
291 (est)+43%
Circassia was founded in 2006 and is headquartered in Oxford, GB
Report incorrect company information

Key People/Management at Circassia

Steve Harris

Steve Harris

Chief Executive Officer
Julien Cotta

Julien Cotta

Chief Financial Officer
Dr Rod Hafner

Dr Rod Hafner

Senior Vice President Research & Development
David L Acheson

David L Acheson

Senior Vice President US Commercial
Darren Mercer

Darren Mercer

Senior Vice President EU & RoW Commercial
Nina Kataria

Nina Kataria

Senior Vice President Global Human Resources
Show more

Circassia Office Locations

Circassia has offices in Oxford, Chicago and Solna
Oxford, GB (HQ)
The Oxford Science Park
Solna, SE
18 Råsundavägen
Chicago, US
101 North Wacker Drive Suite 100
Show all (3)
Report incorrect company information

Circassia Financials and Metrics

Circassia Financials

Circassia's revenue was reported to be £17 k in FY, 2016

Revenue (FY, 2016)

17 k

Net income (FY, 2016)

17 k

EBITDA (FY, 2016)

17 k

EBIT (FY, 2016)

17 k

Market capitalization (31-Oct-2017)

255.3 m

Closing share price (31-Oct-2017)

Circassia's current market capitalization is £255.3 m.
GBPFY, 2008FY, 2009FY, 2013FY, 2014FY, 2015FY, 2016


17 k


(624.7 k)(362.3 k)(188 k)(3 k)17 k

EBITDA margin, %



(624.7 k)(362.3 k)(295 k)(3 k)17 k
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Accounts Receivable

1 17.2 k104.4 k27 k1 k

Current Assets

19.6 k1 1 17.2 k104.4 k27 k1 k

Total Assets

19.6 k1 106.8 k124 k211.2 k27 k1 k

Accounts Payable

190.5 k34.6 k84.7 k154.3 k21 k
GBPFY, 2008FY, 2009FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(624.7 k)(362.3 k)(269 k)(2 k)(1 k)17 k

Income Taxes Paid

26 k1 k(1 k)
Show all financial metrics
Report incorrect company information

Circassia News and Updates

Remembering when European migrants once flocked to North African shores

“Praise be to God. To my master, may god preserve you. After our master scolded me and became angry with me, accusing me of having…

Allergy Treatment Global Market 2018: Key Players – ALK, Stallergenes Greer, Allergy Therapeutics, HAL Allergy Group, Circassia

Allergy Treatment -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

World Allergy Immunotherapy Market is Estimated to Reach USD 4,324.7 million by 2023

Market Research Future published a cooked research report on “Global Allergy Immunotherapy Market Research Report - Forecast to 2023” – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information